Comparison · NCT04981717-sae
R1908-1909 600 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. R1908-1909 600 mg vs Placebo: serious adverse events. Trial comparisons, record NCT04981717-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04981717-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00917 | 0.00252 | 0.0328 | wilson | |
| Risk in group 2 | 0.00901 | 0.00247 | 0.0322 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000165 | -0.024 | 0.0247 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.145 | 7.17 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.142 | 7.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on R1908-1909 600 mg than on Placebo | 6,050 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | R1908-1909 600 mg | Randomized 1:1 ratio of REGN1908-1909 600 mg administered Q12W for a total of 5 administrations | 2 | 218 | EG001 |
| Group 2 | Placebo | Randomized 1:1 ratio of matching placebo for REGN1908-1909 600 mg administered Q12W for a total of 5 administrations | 2 | 222 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose to study termination (~60 weeks)
Source ClinicalTrials.gov
Trial
- Title
- A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
- NCT number
- NCT04981717
- Phases
- PHASE3
- Conditions
- Allergic Rhinitis Due to Cat Allergy
- Interventions
- REGN1908-1909, Matching Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2024-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04981717?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04981717-sae